Dr. Martin Sadowski

Dr. Martin Sadowski is a physician–scientist with a career-long focus on translational research in Alzheimer’s disease (AD). Dr. Sadowski received his MD degree in 1995 and PhD degree in neuroscience in 1996 from the Medical University of Gdansk in Gdansk, Poland. Between 1996 and 1998, he underwent postdoctoral training in experimental neuropathology under the mentorship of Dr. Henry M. Wisniewski in the New York State Institute for Basic Research on Staten Island, NY. Dr. Sadowski is now a Tenured Professor in the Departments of Neurology, Psychiatry, and Biochemistry and Molecular Pharmacology at the NYU School of Medicine, where he directs the Alzheimer's Clinical Trial Program and the Laboratory for Alzheimer’s Therapeutics. Dr. Sadowski has been the site PI for over 35 industry-sponsored AD clinical trials, while his laboratory has been successfully pursuing several long-term projects focused on the role of apoE in AD pathogenesis, targeting the apoE/Aß interaction as a therapeutic approach for AD, mechanisms underlying differential effects of various apoE isoforms in the susceptibility to sporadic AD and response to anti-Aß immunotherapy, immunotherapy for prionoses, the role of peroxiredoxin 6 in neurodegeneration, and targeting APP translation for AD therapy. Dr. Sadowski has co-authored 130 publications in the field of AD and neurodegeneration and has served on numerous NIH study sections.